Loading...
•
Jun 30, 2024
PMV Pharma Q2 2024 Earnings Report
Reported financial results for the second quarter ended June 30, 2024 and provided an update on the Phase 2 monotherapy and Phase 1b combination portions of the PYNNACLE clinical trial.
Key Takeaways
PMV Pharmaceuticals reported financial results for the second quarter ended June 30, 2024. The company's net loss for the quarter was $1.2 million, and they ended the quarter with $212.9 million in cash, cash equivalents, and marketable securities.
Enrollment is on track in Phase 2 portion of PYNNACLE clinical trial.
Eligibility criteria in ongoing Phase 1b rezatapopt and pembrolizumab combination arm of PYNNACLE trial adjusted to align with Phase 2 TP53 Y220C and KRAS wild-type patient population.
Cash, cash equivalents, and marketable securities of $212.9 million as of June 30, 2024, providing expected cash runway to end of 2026.
Net loss for the quarter ended June 30, 2024, was $1.2 million.